摘要
目的 观察达格列净治疗老年射血分数降低性心力衰竭(心衰)患者的疗效及安全性。方法 选取合肥市第二人民医院2019年1月至2021年6月诊断为射血分数降低性心衰的老年患者,采取随机数字表法将患者分为对照组(100例)和观察组(100例)。对照组患者用常规抗心衰药物给予治疗,观察组患者在此基础上加用达格列净,比较治疗前后两组患者左心室射血分数(left ventricular ejection fraction,LVEF)、左心室舒张末期内径(left ventricular end-diastolic diameter,LVEDD)、左心室收缩末期内径(left ventricular end-systolic diameter,LVESD)、氨基末端脑钠肽前体(N-terminal pro-brain natriuretic peptide,NT-proBNP)、估算肾小球滤过率(estimated glomerular filtration rate,eGFR)、6 min步行距离(6 minute walking distance,6MWD)及不良反应。结果 观察组患者的LVEF、LVESD、LVEDD、NT-proBNP、eGRF及6MWD改善均较对照组显著,差异具有统计学意义(P<0.05)。两组患者的eGFR均较治疗前有所下降,但组间比较差异无统计学意义(P>0.05)。观察组有5例患者出现低血糖反应,对照组无药物不良反应发生。结论 达格列净可改善老年射血分数降低性心衰患者心脏功能,抑制心室重构,且不良反应较低,具有进一步研究的价值。
Objectives To observe the efficacy and safety of dapagliflozin in the treatment of heart failure with reduced ejection fraction(HFrEF)in the elderly patients.Methods Elderly patients diagnosed with HFrEF in Hefei Second People′s Hospital from January 2019 to June 2021 were selected and divided into a control group(n=100)and an observation group(n=100)according to the random number table method.Control group was treated with conventional drugs for heart failure,and observation group was treated with dalglitazin on the basis of control group.The left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD),N-terminal pro-brain natriuretic peptide(NT-proBNP),estimated glomerular filtration rate(eGFR),adverse reactions and 6 minute walking distance(6MWD)were compared between the two groups before and after treatment.Results The LVEF,LVESD,LVEDD,NT-proBNP,eGFR and 6MWD of observation group improved significantly compared with those of control group,and the differences were statistically significant(P<0.05).The eGFR of the two groups decreased compared with that before treatment,but there was no significant difference between the two groups(P>0.05).There were 5 patients in observation group who had hypoglycemia,and there were no adverse drug reactions in control group.Conclusions Dapagliflozin can improve heart function in elderly patients with HFrEF,inhibit ventricular remodeling,with few adverse reactions and has the value of further research.
作者
倪润泽
冯俊
NI Runze;FENG Jun(Department of Cardiology,Hefei Hospital Affiliated to Anhui Medical University(Hefei Second People′s Hospital),Hefei 230011,China;The Fifth Clinical Hospital of Anhui Medical University,Hefei 230032,China)
出处
《岭南心血管病杂志》
CAS
2023年第1期68-73,共6页
South China Journal of Cardiovascular Diseases
基金
蚌埠医学院自然科学重点项目(编号:BYKY2019301ZD)
安徽医科大学科研基金(编号:2019xkj086)。
关键词
心力衰竭
达格列净
临床疗效
安全性
heart failure
dapagliflozin
clinical efficacy
safety
